Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Sonoma Pharmaceuticals, Inc. (SNOA)

Sonoma Pharmaceuticals Raises At-the-Market Share Sale Capacity to $3.64 Million

Neutral Impact 3 of 5 financing Written later

Sonoma Pharmaceuticals filed a prospectus supplement increasing the aggregate offering price under its at-the-market share sales agreement with Ladenburg Thalmann to $3,641,703. Since September 26, 2025, the company has sold 173,073 shares for $574,633, so the larger amount gives it room to raise more equity from the program, which could dilute existing shareholders.

Key points

  • Shares sold under the agreement from September 26, 2025 through the filing date: 173,073 shares for $574,633
  • Aggregate offering price raised to $3,641,703 via a supplement filed June 18, 2026
  • Shares previously registered but not yet sold total $1,495,830

The filing

CompanySonoma Pharmaceuticals, Inc. (SNOA)
Form8-K, current report
Filed with the SECJun 18, 2026, 4:33 PM ET
Accession number0001683168-26-004975

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 18, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.